

Intravenous Recombinant Tissue Plasminogen Activator (Rt-PA) Induced Life-Threatening Angioedema

Szu-chi Chen, MD¹, Yue-Ying Li, MD¹, Hung-Kai Lo, MD¹, Hann-Yeh Shyu, MD^{2,3}, Ming-Hua Chen, MD^{2,3} and Po-Jen Hsiao, MD, PhD^{4,5,6}

¹Department of Internal Medicine, Taoyuan Armed Forces General Hospital, Taoyuan, Taiwan

²Division of Neurology, Department of Internal Medicine, Taoyuan, Armed Forces General Hospital, Taoyuan, Taiwan

³Department of Neurology, Tri-Service General Hospital, National Defense Medical University, Taipei, Taiwan

⁴Division of Nephrology, Department of Internal Medicine, Taoyuan, Armed Forces General Hospital, Taoyuan, Taiwan

⁵Division of Nephrology, Department of Internal Medicine, Tri-Service General Hospital, National Defense Medical University, Taipei, Taiwan

⁶Department of Life Sciences, National Central University, Taoyuan, Taiwan

*Corresponding author:

Po-Jen Hsiao, MD,
Division of Nephrology, Department of Internal
Medicine, Taoyuan Armed Forces General Hos-
pital, Taiwan No.168, Zhongxing Rd., Longtan
Dist., Taoyuan City 325, Taiwan

Received: 02 Feb 2026

Accepted: 13 Feb 2026

Published: 18 Feb 2026

J Short Name: ACMCR

Copyright:

©2026 Po-Jen Hsiao. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and build upon your work non-commercially

Author Contribution: Po-Jen Hsiao and Ming-Hua Chen contributed equally to this work

Keywords:

Intravenous Recombinant Tissue Plasminogen Activator (rt-PA); Angioedema

Citation:

Po-Jen Hsiao, Intravenous Recombinant Tissue Plasminogen Activator (Rt-PA) Induced Life-Threatening Angioedema. Ann Clin Med Case Rep® 2026; V15(1): 1-3

1. Abstract

An 85-year-old woman with a prior cerebrovascular accident presented with sudden right-sided weakness and aphasia (NIHSS 15). She received intravenous recombinant tissue plasminogen activator (rt-PA) followed by successful mechanical thrombectomy for an acute left M1 occlusion. Within two hours, she developed right-sided neck swelling, ecchymosis, dyspnea, and stridor. Prophylactic endotracheal intubation was performed, and methylprednisolone and diphenhydramine were administered. Her airway stabilized without haemorrhagic complications. Neurological function gradually improved, and she was extubated after 10 days. The patient achieved a satisfactory recovery and remained well without sequelae at 6-month follow-up. rt-PA induced neck angioedema is rare but may be life-threatening. Early recognition of rt-PA-induced angioedema associated complications and prompt management are crucial to prevent fatal complications.

2. Introduction

Angioedema without accompanying urticaria is a recognized and potentially serious complication in patients receiving the recombinant tissue-type plasminogen activator (r-tPA) alteplase or its modified form, Tenecteplase, for acute ischemic stroke, with reported incidence ranging from 0.4% to 5.1% [1-5]. This condition manifests as nonpitting, nonpruritic swelling of the skin or mucous membranes resulting from transient increases in vascular permeability. When induced by r-tPA, angioedema

typically affects the head and neck region, posing a significant risk of airway compromise and potentially fatal obstruction. Multiple biological pathways can lead to angioedema, and several mediators have been implicated, including bradykinin, histamine, substance P, prostaglandins, and leukotrienes. Because the effectiveness of treatment differs across these mechanisms, accurately identifying the predominant mediator is essential for guiding appropriate, individualized therapy.

Although existing clinical guidelines advise the initial use of epinephrine and antihistamines when managing isolated r-tPA-induced angioedema, growing evidence suggests that this strategy may not fully address the underlying pathophysiology in many cases. Increasing data indicate that bradykinin plays a central role in r-tPA-associated angioedema, especially given its involvement in vasodilation and increased vascular permeability. Therefore, the experts advocate for therapeutic approaches that prioritize modulation of the bradykinin pathway [6], such as agents targeting bradykinin receptors or inhibiting its production or downstream effects. This shift in focus may improve outcomes by offering more targeted control of the angioedema process, particularly in patients who do not respond adequately to conventional antihistamine- and epinephrine-based regimens. Overall, optimizing the management of r-tPA-induced angioedema requires greater attention to the underlying mechanisms, with growing support for bradykinin-centered strategies as a more physiologically appropriate and potentially more effective first-line treatment option.

3. Case Report

An 85-year-old woman with a history of an old cerebrovascular accident presented to the outpatient department with sudden onset of right-sided weakness and aphasia. She was immediately transferred to the emergency department for further evaluation. On arrival, her National Institutes of Health Stroke Scale (NIHSS) score was 15. After consultation with a neurologist, intravenous recombinant tissue plasminogen activator (rt-PA) was administered. The patient subsequently underwent endovascular thrombectomy, which revealed an acute occlusion of the left middle cerebral artery (M1 segment), and successful mechanical thrombectomy was performed. Within two hours after

rt-PA administration, non-pitting swelling and ecchymosis over the right side of her neck were noted (Figure 1). Physical examination revealed obvious dyspnea and stridor. For airway protection, prophylactic endotracheal intubation was performed after discussion with the patient and her family. Intravenous methylprednisolone (125 mg) and diphenhydramine (60 mg) were administered immediately in addition to airway management. Following the above interventions, gradual improvement in muscle strength on the right side was observed. No hemorrhagic complications occurred during hospitalization. The patient was successfully extubated after 10 days. She was discharged with a satisfactory recovery. After a 6-month follow-up, she remained well without sequelae.



Figure 1: Non-pitting swelling and ecchymosis over the right side of the neck developed within two hours after administration of intravenous recombinant tissue plasminogen activator (rt-PA).

4. Discussion

Angioedema has been reported to occur in patients treated with alteplase or Tenecteplase for acute ischemic stroke [1-6]. It is typically mild, transient, and often manifests contralateral to the ischemic hemisphere. rt-PA-induced angioedema usually involves the head and neck region, where it may lead to airway obstruction and potentially life-threatening complications [3, 4]. Because upper airway compromise can develop rapidly, clinicians should maintain a high index of suspicion and initiate prompt airway protection when necessary.

The onset of angioedema has been reported to range from 5 to 189 minutes after the initiation of rt-PA infusion, with a median onset time of approximately 65 minutes [7, 8]. Therefore, close monitoring of patients for several hours following rt-PA administration is strongly recommended to detect any early signs of airway involvement. The proposed mechanism of rt-PA-induced angioedema involves vasodilation and increased vascular permeability mediated by inflammatory pathways, primarily through bradykinin activation. Patients receiving angiotensin-converting enzyme (ACE) inhibitors and those with computed tomogra-

phy (CT) evidence of ischemia involving the frontal and insular cortex appear to have an increased risk of developing angioedema [9]. Consequently, the use of ACE inhibitors for blood pressure control should be avoided immediately prior to rt-PA administration. Although current guidelines recommend initial management with epinephrine and antihistamines for isolated rt-PA-induced angioedema, several reports suggest that treatment targeting the bradykinin-mediated pathway may provide a more effective therapeutic approach [10]. Further research is warranted to establish optimal management strategies for this potentially fatal complication.

5. Funding

This study was supported by grant TYAFGH-D-114032 and TYAFGH-D-114039 from the Taoyuan Armed Forces General Hospital, Taiwan.

References

1. Menon BK, Buck BH, Singh N, Deschaintre Y, Almekhlafi MA. AcT Trial Investigators. Intravenous tenecteplase compared with alteplase for acute ischaemic stroke in Canada (AcT): a pragmatic, multicentre, open-label, registry-linked, randomised, controlled, non-inferiority trial. *Lancet*. 2022; 400: 161-9.
2. Rose D, Cavalier A, Kam W, Cantrell S, Lusk J. Complications of intravenous tenecteplase versus alteplase for the treatment of acute ischemic stroke: a systematic review and meta-analysis. *Stroke*. 2023; 54: 1192-204
3. Hill MD, Lye T, Moss H, Barber PA, Demchuk AM. Hemi-orolingual angioedema and ACE inhibition after alteplase treatment of stroke. *Neurology*. 2003; 60: 1525-27.
4. Myslimi F, Caparros F, Dequatre-Ponchelle N, Moulin S, Gautier S. Orolingual angioedema during or after thrombolysis for cerebral ischemia. *Stroke*. 2016; 47: 1825-30.
5. Flint AC, Eaton A, Melles RB, Hartman J, Cullen SP. Comparative safety of tenecteplase vs alteplase for acute ischemic stroke. *J. stroke Cerebrovasc. Dis.: Off. J. Natl. Stroke Assoc.* 2023; 33: 107468.
6. Powers WJ, Rabinstein AA, Ackerson T, Adeoye OM. Guidelines for the early management of patients with acute ischemic stroke: 2019 update to the 2018 guidelines for the early management of acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. *Stroke*. 2019; 50: e344-e418.
7. Cathy S Zhong, James Beharry, Daniel Salazar, Kelly Smith, Stephen Withington. Routine Use of Tenecteplase for Thrombolysis in Acute Ischemic Stroke. *Stroke* 2021; 52: 1087-90.
8. Robert Hurford, Sean Rezvani, Mohammad Kreimeh, Annie Herbert. Incidence, predictors and clinical characteristics of orolingual angio-oedema complicating thrombolysis with tissue plasminogen activator for ischaemic stroke. *J Neurol Neurosurg Psychiatry* 2015; 86: 520-3.
9. Miguel Mas-Serrano, Andrés García-Pastor, Ana María Iglesias-Mohedano, Fernando Díaz-Otero. Related factors with orolingual angioedema after intravenous alteplase in acute ischemic stroke: results from a single-center cohort and meta-analysis. *Neurol Sci* 2022; 43: 441-52.
10. Evelien M Hutten, Annick A J M van de Ven, Rik Mencke, Rick G Pleijhuis. Angioedema After Use of Recombinant Tissue-Type Plasminogen Activators in Stroke *Stroke* 2024; 55: 2193-7.